卡培他滨治疗进展期三阴性乳腺癌疗效分析  

Retrospective Analysis of Capecitabine in Routine Treatment of Advanced Triple Negative-breast Carcinoma

作　　者：高会全[1,2] 马学真[3] 朱超[3] 董桂芝[2] 杜朝晖 申文江[4] 

机构地区：[1]青岛大学医学院肿瘤学系,山东青岛266021 [2]解放军第四零四医院肿瘤中心 [3]青岛大学医学院附属二院肿瘤科 [4]北京大学第一医院放疗科

出　　处：《肿瘤防治研究》2014年第4期383-386,共4页Cancer Research on Prevention and Treatment

摘　　要：目的观察卡培他滨在未经选择的进展期三阴性乳腺癌患者治疗中的疗效和不良反应。方法收集青岛大学医学院附属二院肿瘤科采用卡培他滨单药或联合化疗的进展期三阴性乳腺癌病例45例,回顾分析其近期疗效、无进展生存时间(PFS)和不良反应。结果中位随访8月,所有患者总有效率为60%。卡培他滨联合用药组有效率66.7%,单药组有效率33.3%,两者比较差异有统计学意义(P=0.028)。所有患者中位PFS为7.75月。单药组和联合组中位PFS分别为9.25月和7.55月,差异无统计学意义(P=0.751)。基础体能状况是PFS的重要预测因素(P=0.005)。无复发间期是否大于2年(P=0.198)不是PFS的预测因素。主要不良反应为手足综合征、胃肠道反应及骨髓抑制。结论卡培他滨治疗进展期三阴性乳腺癌具有较好的疗效,不良反应可耐受。日常临床实践中疗效与干预性临床试验结果相同。Objective To observe the efficacy and adverse reaction of capecitabine in routine clinical practice for unselected advanced triple negative-breast cancer(TNBC). Methods Forty-five advanced TNBC patients with capecitabine monotherapy or combined chemotherapy were collected by The Second Affiliated Hospital to Medical College of Qingdao University. The short-term efficacy, progression-free survival(PFS), and adverse reaction were analyzed retrospectively. Results Overall response rate(ORR) was 60% after 8 months of median follow-up. Response rate of combined chemotherapy group and monotherapy group was 66.7% and 33.3% respectively(P=0.028). Good performance status at baseline was a signifi cant predictor of effi cacy(P=0.005). Relapse-free interval after surgery(P=0.198) was not signifi cant predictor of PFS. The most common toxicity was hand-foot syndrome, gastrointestinal reaction and myelosuppression. Conclusion Capecitabine is a feasible, effective and well tolerated treatment for advanced TNBC. The effi cacy in real-life clinical practice is as same as results from interventional studies.

关 键 词：三阴性乳腺癌 卡培他滨 回顾分析 

分 类 号：R737.9[医药卫生—肿瘤]